Natera enters the stretch toward its June 11 earnings with one of its most distinctly bullish options setups of the past year — a sharp contrast to a stock that has still not recovered all of last month's post-earnings damage.
The options market is sending the clearest signal right now. The put/call ratio has dropped to 0.50, nearly two standard deviations below its 20-day average of 0.63, making it the most call-heavy reading this PCR has seen in months. For context, the ratio was running above 0.73 for most of April, when macro anxiety and the earnings overhang had options traders hedging heavily. The abrupt rotation toward calls in the past week — the PCR has fallen from 0.64 to 0.50 in five sessions — points to a meaningful shift in positioning. The 52-week range runs from 0.29 to 1.24, so the current reading is not at an extreme, but the pace of the move is notable.
Short interest tells a quieter story. At roughly 2.9% of free float, bears have not exactly piled in — and the one-month picture is actually one of unwinding, with SI down about 18% from the late-April spike that briefly pushed the float-weighted ratio above 3.6%. That spike coincided with the period immediately ahead of the May 7 earnings print, when shorts were building. After the results — which sent the stock down nearly 10% on the day — that crowd largely covered. Borrow remains cheap at around 0.42% annualised, a level that has crept up roughly 11% on the week but remains far below anything that would suggest real squeeze pressure. And with availability running above 8,000% of short interest, the lending pool is effectively unlimited; there is no supply constraint for anyone wanting to initiate a short position.
The Street, by contrast, has been constructive since the results hit. JP Morgan raised its target to $265 from $260 last week, maintaining Overweight. Evercore ISI moved to $270 from $250 on the same day. BTIG trimmed modestly to $250 from $260 but kept its Buy. The consensus mean target now sits around $261, implying roughly 33% upside to the current price of $196. The bull case rests on Natera's leadership in non-invasive prenatal testing, the Signatera MRD franchise in oncology, and evidence from its FIND CRC colorectal screening study. Bears flag reimbursement risk, growing competition in all three core markets, and execution risk around the recent Foresight Diagnostics acquisition. Valuation offers no conventional anchor — the company is unprofitable, P/E is deeply negative, and the price-to-book of around 14x reflects a premium for growth rather than current earnings power.
The institutional picture is broadly supportive. T. Rowe Price is the largest holder at 9.3% of shares, and added nearly 2.4 million shares as of March-end. JP Morgan Asset Management, Vanguard, and BlackRock together account for another 24% of shares outstanding, with each adding modestly in the most recent reported period. One notable outflow: Farallon Capital trimmed by 707,000 shares in Q1. Insider activity has been routine — founder Jonathan Sheena sold small tranches across May 8 and May 13 at prices between $199 and $208, totalling around $630,000. The 90-day net insider value is positive at roughly $3.6 million, though that figure appears to reflect option exercises and grants rather than open-market conviction buying.
The recent earnings history gives some context for what the June 11 event could bring. The May 7 Q1 report produced a 9.7% single-day drop and a 8.5% drawdown over the following five sessions — a pattern that validated the pre-earnings hedging. The stock has clawed back about half of those losses since then, but is still down 4% on the week and 6% over the past month. Peer context is mixed: VCYT gained 5.4% on the week while CAI and TWST both fell more than 10%, suggesting the sector has no clear directional bid. NTRA's 4% weekly decline lands it roughly in the middle of that peer group.
The ORTEX short score of 33.8 is moderate, the 90-day EPS momentum factors are soft (ranked in the 10th–14th percentile), and the forward EPS growth outlook remains in the 81st percentile. The key tension heading into June 11 is whether the Street's optimism on Signatera and colorectal cancer screening can shift the earnings narrative away from the miss-and-drop template set last quarter — and whether the call-heavy options positioning reflects genuine conviction or simply a tactical hedge in the opposite direction.
See the live data behind this article on ORTEX.
Open NTRA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
